CN1507564A - 免疫反应测定方法以及方法中使用的免疫反应测定用试剂盒 - Google Patents
免疫反应测定方法以及方法中使用的免疫反应测定用试剂盒 Download PDFInfo
- Publication number
- CN1507564A CN1507564A CNA028097041A CN02809704A CN1507564A CN 1507564 A CN1507564 A CN 1507564A CN A028097041 A CNA028097041 A CN A028097041A CN 02809704 A CN02809704 A CN 02809704A CN 1507564 A CN1507564 A CN 1507564A
- Authority
- CN
- China
- Prior art keywords
- mentioned
- reaction system
- antibody
- antigen
- immunoreaction measurement
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003153 chemical reaction reagent Substances 0.000 title description 15
- 238000003018 immunoassay Methods 0.000 title description 6
- XNGIFLGASWRNHJ-UHFFFAOYSA-N phthalic acid Chemical compound OC(=O)C1=CC=CC=C1C(O)=O XNGIFLGASWRNHJ-UHFFFAOYSA-N 0.000 claims abstract description 307
- 238000006243 chemical reaction Methods 0.000 claims abstract description 208
- 239000000427 antigen Substances 0.000 claims abstract description 105
- 102000036639 antigens Human genes 0.000 claims abstract description 105
- 108091007433 antigens Proteins 0.000 claims abstract description 105
- 239000000126 substance Substances 0.000 claims abstract description 55
- 230000003287 optical effect Effects 0.000 claims abstract description 15
- 230000036046 immunoreaction Effects 0.000 claims description 151
- XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 claims description 106
- 238000005259 measurement Methods 0.000 claims description 90
- 239000000463 material Substances 0.000 claims description 84
- 238000000691 measurement method Methods 0.000 claims description 77
- 102100032752 C-reactive protein Human genes 0.000 claims description 68
- IWZKICVEHNUQTL-UHFFFAOYSA-M potassium hydrogen phthalate Chemical compound [K+].OC(=O)C1=CC=CC=C1C([O-])=O IWZKICVEHNUQTL-UHFFFAOYSA-M 0.000 claims description 57
- 238000000034 method Methods 0.000 claims description 53
- 239000006172 buffering agent Substances 0.000 claims description 36
- 150000001455 metallic ions Chemical class 0.000 claims description 30
- 229920000151 polyglycol Polymers 0.000 claims description 30
- 239000010695 polyglycol Substances 0.000 claims description 30
- 108010074051 C-Reactive Protein Proteins 0.000 claims description 13
- 230000005540 biological transmission Effects 0.000 claims description 5
- 229910000765 intermetallic Inorganic materials 0.000 claims description 2
- 230000027455 binding Effects 0.000 abstract description 6
- 230000009870 specific binding Effects 0.000 abstract 3
- 238000013016 damping Methods 0.000 description 124
- 239000012530 fluid Substances 0.000 description 124
- 239000000243 solution Substances 0.000 description 122
- 102000008100 Human Serum Albumin Human genes 0.000 description 54
- 108091006905 Human Serum Albumin Proteins 0.000 description 54
- 230000000694 effects Effects 0.000 description 45
- 150000001875 compounds Chemical class 0.000 description 30
- 238000002360 preparation method Methods 0.000 description 28
- KKEYFWRCBNTPAC-UHFFFAOYSA-N Terephthalic acid Chemical compound OC(=O)C1=CC=C(C(O)=O)C=C1 KKEYFWRCBNTPAC-UHFFFAOYSA-N 0.000 description 26
- 238000004848 nephelometry Methods 0.000 description 26
- DVLFYONBTKHTER-UHFFFAOYSA-N 3-(N-morpholino)propanesulfonic acid Chemical compound OS(=O)(=O)CCCN1CCOCC1 DVLFYONBTKHTER-UHFFFAOYSA-N 0.000 description 25
- 239000000523 sample Substances 0.000 description 25
- 239000007993 MOPS buffer Substances 0.000 description 24
- 230000000052 comparative effect Effects 0.000 description 19
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 19
- 239000000203 mixture Substances 0.000 description 17
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 15
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 15
- 238000004879 turbidimetry Methods 0.000 description 13
- 229920003169 water-soluble polymer Polymers 0.000 description 13
- 102000009027 Albumins Human genes 0.000 description 12
- 108010088751 Albumins Proteins 0.000 description 12
- 239000000872 buffer Substances 0.000 description 12
- 230000036039 immunity Effects 0.000 description 11
- 230000004520 agglutination Effects 0.000 description 10
- 238000005755 formation reaction Methods 0.000 description 10
- 230000007935 neutral effect Effects 0.000 description 9
- 101000942118 Homo sapiens C-reactive protein Proteins 0.000 description 8
- 101000922020 Homo sapiens Cysteine and glycine-rich protein 1 Proteins 0.000 description 8
- 239000007864 aqueous solution Substances 0.000 description 8
- 102000051143 human CRP Human genes 0.000 description 8
- 239000007788 liquid Substances 0.000 description 8
- -1 phthalic acid ion Chemical class 0.000 description 8
- 238000012545 processing Methods 0.000 description 8
- 239000010453 quartz Substances 0.000 description 8
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicon dioxide Inorganic materials O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 8
- 241001482592 Oreamnos americanus Species 0.000 description 7
- 238000003556 assay Methods 0.000 description 7
- 230000015572 biosynthetic process Effects 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 7
- 210000004408 hybridoma Anatomy 0.000 description 7
- 239000006193 liquid solution Substances 0.000 description 7
- 238000002156 mixing Methods 0.000 description 7
- 230000035945 sensitivity Effects 0.000 description 7
- 239000001384 succinic acid Substances 0.000 description 7
- 206010003445 Ascites Diseases 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- QQVIHTHCMHWDBS-UHFFFAOYSA-N isophthalic acid Chemical compound OC(=O)C1=CC=CC(C(O)=O)=C1 QQVIHTHCMHWDBS-UHFFFAOYSA-N 0.000 description 6
- 101710153593 Albumin A Proteins 0.000 description 5
- 238000004440 column chromatography Methods 0.000 description 5
- 230000001419 dependent effect Effects 0.000 description 5
- 238000010790 dilution Methods 0.000 description 5
- 239000012895 dilution Substances 0.000 description 5
- 238000005065 mining Methods 0.000 description 5
- 235000015097 nutrients Nutrition 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 241000283973 Oryctolagus cuniculus Species 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- 239000001963 growth medium Substances 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- XCCFSZODNJHPEF-UHFFFAOYSA-N 2-carboxybenzoate;hydron;potassium Chemical compound [K].OC(=O)C1=CC=CC=C1C(O)=O XCCFSZODNJHPEF-UHFFFAOYSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 239000012980 RPMI-1640 medium Substances 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000000621 autoagglutination Effects 0.000 description 3
- OSKNUZYLXFBIHL-UHFFFAOYSA-N azanium;hydron;phthalate Chemical compound N.OC(=O)C1=CC=CC=C1C(O)=O OSKNUZYLXFBIHL-UHFFFAOYSA-N 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- VYGAQHDGEYQIJU-UHFFFAOYSA-N butanedioic acid;phthalic acid Chemical compound OC(=O)CCC(O)=O.OC(=O)C1=CC=CC=C1C(O)=O VYGAQHDGEYQIJU-UHFFFAOYSA-N 0.000 description 3
- 238000013098 chemical test method Methods 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- GSCLWPQCXDSGBU-UHFFFAOYSA-L copper;phthalate Chemical compound [Cu+2].[O-]C(=O)C1=CC=CC=C1C([O-])=O GSCLWPQCXDSGBU-UHFFFAOYSA-L 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 238000000502 dialysis Methods 0.000 description 3
- 238000006073 displacement reaction Methods 0.000 description 3
- 239000012149 elution buffer Substances 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 230000000116 mitigating effect Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- ZXKXJHAOUFHNAS-FVGYRXGTSA-N (S)-fenfluramine hydrochloride Chemical compound [Cl-].CC[NH2+][C@@H](C)CC1=CC=CC(C(F)(F)F)=C1 ZXKXJHAOUFHNAS-FVGYRXGTSA-N 0.000 description 2
- UMCMPZBLKLEWAF-BCTGSCMUSA-N 3-[(3-cholamidopropyl)dimethylammonio]propane-1-sulfonate Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCC[N+](C)(C)CCCS([O-])(=O)=O)C)[C@@]2(C)[C@@H](O)C1 UMCMPZBLKLEWAF-BCTGSCMUSA-N 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 2
- 206010029164 Nephrotic syndrome Diseases 0.000 description 2
- RCEAADKTGXTDOA-UHFFFAOYSA-N OS(O)(=O)=O.CCCCCCCCCCCC[Na] Chemical compound OS(O)(=O)=O.CCCCCCCCCCCC[Na] RCEAADKTGXTDOA-UHFFFAOYSA-N 0.000 description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
- 101710120037 Toxin CcdB Proteins 0.000 description 2
- KGUHOFWIXKIURA-VQXBOQCVSA-N [(2r,3s,4s,5r,6r)-6-[(2s,3s,4s,5r)-3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]oxy-3,4,5-trihydroxyoxan-2-yl]methyl dodecanoate Chemical class O[C@@H]1[C@@H](O)[C@H](O)[C@@H](COC(=O)CCCCCCCCCCC)O[C@@H]1O[C@@]1(CO)[C@@H](O)[C@H](O)[C@@H](CO)O1 KGUHOFWIXKIURA-VQXBOQCVSA-N 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 230000009920 chelation Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 2
- 229910000397 disodium phosphate Inorganic materials 0.000 description 2
- 235000019800 disodium phosphate Nutrition 0.000 description 2
- CCIVGXIOQKPBKL-UHFFFAOYSA-N ethanesulfonic acid Chemical compound CCS(O)(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-N 0.000 description 2
- 229930182478 glucoside Natural products 0.000 description 2
- 235000013905 glycine and its sodium salt Nutrition 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 2
- 235000019799 monosodium phosphate Nutrition 0.000 description 2
- 201000000050 myeloid neoplasm Diseases 0.000 description 2
- 208000009928 nephrosis Diseases 0.000 description 2
- 231100001027 nephrosis Toxicity 0.000 description 2
- NGATWIKLQRJVRN-UHFFFAOYSA-N phthalic acid;sodium Chemical compound [Na].[Na].OC(=O)C1=CC=CC=C1C(O)=O NGATWIKLQRJVRN-UHFFFAOYSA-N 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- XOJVVFBFDXDTEG-UHFFFAOYSA-N pristane Chemical compound CC(C)CCCC(C)CCCC(C)CCCC(C)C XOJVVFBFDXDTEG-UHFFFAOYSA-N 0.000 description 2
- 235000019624 protein content Nutrition 0.000 description 2
- 230000035484 reaction time Effects 0.000 description 2
- 230000002040 relaxant effect Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000001632 sodium acetate Substances 0.000 description 2
- 235000017281 sodium acetate Nutrition 0.000 description 2
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 2
- IHQKEDIOMGYHEB-UHFFFAOYSA-M sodium dimethylarsinate Chemical compound [Na+].C[As](C)([O-])=O IHQKEDIOMGYHEB-UHFFFAOYSA-M 0.000 description 2
- 229910052938 sodium sulfate Inorganic materials 0.000 description 2
- 235000011152 sodium sulphate Nutrition 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 230000000007 visual effect Effects 0.000 description 2
- 108010032595 Antibody Binding Sites Proteins 0.000 description 1
- 101100046775 Arabidopsis thaliana TPPA gene Proteins 0.000 description 1
- 238000011725 BALB/c mouse Methods 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 229920001503 Glucan Polymers 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 240000000233 Melia azedarach Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000218606 Pinus contorta Species 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000013399 early diagnosis Methods 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000012921 fluorescence analysis Methods 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000003163 gonadal steroid hormone Substances 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- TWNIBLMWSKIRAT-VFUOTHLCSA-N levoglucosan Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@H]2CO[C@@H]1O2 TWNIBLMWSKIRAT-VFUOTHLCSA-N 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000006249 magnetic particle Substances 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 230000003071 parasitic effect Effects 0.000 description 1
- 238000005375 photometry Methods 0.000 description 1
- 150000003021 phthalic acid derivatives Chemical class 0.000 description 1
- DFLCZDIXTAAMLZ-UHFFFAOYSA-N phthalic acid;sodium Chemical compound [Na].OC(=O)C1=CC=CC=C1C(O)=O DFLCZDIXTAAMLZ-UHFFFAOYSA-N 0.000 description 1
- 150000003022 phthalic acids Chemical class 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 229920000915 polyvinyl chloride Polymers 0.000 description 1
- 239000004800 polyvinyl chloride Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 239000004065 semiconductor Substances 0.000 description 1
- 239000003352 sequestering agent Substances 0.000 description 1
- 235000000673 shore pine Nutrition 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- GTZCVFVGUGFEME-HNQUOIGGSA-N trans-aconitic acid Chemical compound OC(=O)C\C(C(O)=O)=C/C(O)=O GTZCVFVGUGFEME-HNQUOIGGSA-N 0.000 description 1
- GTZCVFVGUGFEME-UHFFFAOYSA-N trans-aconitic acid Natural products OC(=O)CC(C(O)=O)=CC(O)=O GTZCVFVGUGFEME-UHFFFAOYSA-N 0.000 description 1
- 238000002834 transmittance Methods 0.000 description 1
- XZZNDPSIHUTMOC-UHFFFAOYSA-N triphenyl phosphate Chemical compound C=1C=CC=CC=1OP(OC=1C=CC=CC=1)(=O)OC1=CC=CC=C1 XZZNDPSIHUTMOC-UHFFFAOYSA-N 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 238000013316 zoning Methods 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/536—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase
- G01N33/537—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with separation of immune complex from unbound antigen or antibody
- G01N33/5375—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with separation of immune complex from unbound antigen or antibody by changing the physical or chemical properties of the medium or immunochemicals, e.g. temperature, density, pH, partitioning
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/536—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/536—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase
- G01N33/537—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with separation of immune complex from unbound antigen or antibody
- G01N33/539—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with separation of immune complex from unbound antigen or antibody involving precipitating reagent, e.g. ammonium sulfate
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/536—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase
- G01N33/542—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with steric inhibition or signal modification, e.g. fluorescent quenching
Landscapes
- Health & Medical Sciences (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
Claims (25)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP396381/2001 | 2001-12-27 | ||
JP2001396381 | 2001-12-27 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1507564A true CN1507564A (zh) | 2004-06-23 |
CN1247996C CN1247996C (zh) | 2006-03-29 |
Family
ID=19189082
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN02809704.1A Expired - Lifetime CN1247996C (zh) | 2001-12-27 | 2002-12-27 | 免疫反应测定方法以及方法中使用的免疫反应测定用试剂盒 |
Country Status (6)
Country | Link |
---|---|
US (1) | US7056682B2 (zh) |
EP (1) | EP1369689B1 (zh) |
JP (1) | JP3871677B2 (zh) |
CN (1) | CN1247996C (zh) |
DE (1) | DE60225788T2 (zh) |
WO (1) | WO2003056333A1 (zh) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101957363A (zh) * | 2010-09-13 | 2011-01-26 | 南京卡博生物科技有限公司 | 胶乳免疫比浊检测用样本处理液 |
CN104155456A (zh) * | 2014-08-22 | 2014-11-19 | 山东博科生物产业有限公司 | 一种稳定性强的肌钙蛋白检测试剂盒 |
CN109738348A (zh) * | 2019-01-28 | 2019-05-10 | 大连医科大学 | 基于颗粒计数的免疫凝集反应强度定量分析方法 |
WO2021169343A1 (zh) * | 2020-02-26 | 2021-09-02 | 量准(上海)医疗器械有限公司 | 一种基于等离子光学纳米孔增强免疫比浊的含量测定方法 |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9425138D0 (en) * | 1994-12-12 | 1995-02-08 | Dynal As | Isolation of nucleic acid |
US20030087324A1 (en) * | 1998-02-26 | 2003-05-08 | Yukio Toyoda | Monoclonal antibody for immunologically analyzing or concentrating endocrine disruptor or its degradation product and utilization of the same |
EP1468116A2 (en) | 2002-01-16 | 2004-10-20 | Dynal Biotech ASA | Method for isolating nucleic acids and protein from a single sample |
GB0229287D0 (en) * | 2002-12-16 | 2003-01-22 | Dna Res Innovations Ltd | Polyfunctional reagents |
US7314893B2 (en) | 2005-06-06 | 2008-01-01 | Arkema Inc. | Acrylic copolymers with improved low temperature performance |
JP4231104B2 (ja) * | 2006-09-26 | 2009-02-25 | パナソニック株式会社 | 免疫センサ及びそれを用いた測定方法 |
LU100795B1 (en) * | 2018-05-14 | 2019-11-14 | Diatron MI PLC | Immunoassay for whole blood samples |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS57182169A (en) * | 1981-05-02 | 1982-11-09 | Mitsubishi Chem Ind Ltd | Measuring method for antigen-antibody reaction |
JP2691575B2 (ja) | 1988-08-26 | 1997-12-17 | 第一化学薬品株式会社 | 免疫反応の測定方法 |
US5272258A (en) * | 1989-06-29 | 1993-12-21 | Rush-Presbyterian-St. Luke's Medical Center | Monoclonal antibodies to C-reactive protein |
WO1991000872A1 (en) * | 1989-06-27 | 1991-01-24 | Rush-Presbyterian-St. Luke's Medical Centre | Monoclonal antibodies to c-reactive protein |
US5314804A (en) * | 1992-03-24 | 1994-05-24 | Serim Research Corporation | Test for Helicobacter pylori |
JPH0682450A (ja) * | 1992-09-04 | 1994-03-22 | Eiken Chem Co Ltd | 免疫学的測定試薬 |
US5358852A (en) * | 1992-12-21 | 1994-10-25 | Eastman Kodak Company | Use of calcium in immunoassay for measurement of C-reactive protein |
JP3333569B2 (ja) * | 1993-01-14 | 2002-10-15 | 協和メデックス株式会社 | 免疫測定方法 |
WO1998028623A1 (en) * | 1996-12-20 | 1998-07-02 | Gamera Bioscience Corporation | An affinity binding-based system for detecting particulates in a fluid |
JP3334558B2 (ja) * | 1997-04-23 | 2002-10-15 | 富士レビオ株式会社 | 酵素免疫測定方法及び試験片 |
JPH10332694A (ja) | 1997-06-03 | 1998-12-18 | Sanyo Chem Ind Ltd | 免疫学的測定法 |
JP3886639B2 (ja) | 1998-06-01 | 2007-02-28 | 栄研化学株式会社 | 免疫学的凝集反応試薬およびこれを用いたプロゾーン現象の抑制方法 |
US6617123B1 (en) * | 2000-06-29 | 2003-09-09 | Jack V. Smith | Method for detection of 4-hydroxybutyric acid and its precursor(s) in fluids |
US7172804B2 (en) * | 2001-07-17 | 2007-02-06 | Northwestern University | Film-immobilized capture particles |
US7939283B2 (en) * | 2001-11-01 | 2011-05-10 | Fisher Scientific Company L.L.C. | Analyte binding turbidity assay |
-
2002
- 2002-12-27 JP JP2003556805A patent/JP3871677B2/ja not_active Expired - Fee Related
- 2002-12-27 CN CN02809704.1A patent/CN1247996C/zh not_active Expired - Lifetime
- 2002-12-27 EP EP02790945A patent/EP1369689B1/en not_active Expired - Lifetime
- 2002-12-27 DE DE60225788T patent/DE60225788T2/de not_active Expired - Lifetime
- 2002-12-27 WO PCT/JP2002/013871 patent/WO2003056333A1/ja active IP Right Grant
- 2002-12-27 US US10/474,755 patent/US7056682B2/en not_active Expired - Lifetime
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101957363A (zh) * | 2010-09-13 | 2011-01-26 | 南京卡博生物科技有限公司 | 胶乳免疫比浊检测用样本处理液 |
CN104155456A (zh) * | 2014-08-22 | 2014-11-19 | 山东博科生物产业有限公司 | 一种稳定性强的肌钙蛋白检测试剂盒 |
CN104155456B (zh) * | 2014-08-22 | 2016-11-02 | 山东博科生物产业有限公司 | 一种稳定性强的肌钙蛋白检测试剂盒 |
CN109738348A (zh) * | 2019-01-28 | 2019-05-10 | 大连医科大学 | 基于颗粒计数的免疫凝集反应强度定量分析方法 |
WO2021169343A1 (zh) * | 2020-02-26 | 2021-09-02 | 量准(上海)医疗器械有限公司 | 一种基于等离子光学纳米孔增强免疫比浊的含量测定方法 |
WO2021168877A1 (zh) * | 2020-02-26 | 2021-09-02 | 量准(上海)医疗器械有限公司 | 一种基于等离子光学纳米孔增强免疫比浊的含量测定方法 |
Also Published As
Publication number | Publication date |
---|---|
WO2003056333A1 (fr) | 2003-07-10 |
EP1369689A4 (en) | 2005-09-28 |
JP3871677B2 (ja) | 2007-01-24 |
DE60225788D1 (de) | 2008-05-08 |
CN1247996C (zh) | 2006-03-29 |
DE60225788T2 (de) | 2008-07-17 |
US7056682B2 (en) | 2006-06-06 |
EP1369689A1 (en) | 2003-12-10 |
US20040121417A1 (en) | 2004-06-24 |
EP1369689B1 (en) | 2008-03-26 |
JPWO2003056333A1 (ja) | 2005-05-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1463364A (zh) | 免疫反应测定方法及其所使用的免疫反应测定试剂 | |
JP5807300B2 (ja) | 試料中のc反応性蛋白質の測定方法及び測定試薬 | |
CN1247996C (zh) | 免疫反应测定方法以及方法中使用的免疫反应测定用试剂盒 | |
CN1227532C (zh) | 高灵敏度的免疫检测方法 | |
CN102662061B (zh) | 胶乳增强免疫比浊法测定人甲胎蛋白含量的试剂盒 | |
CN101351707B (zh) | 凝集测量用试剂以及凝集测量方法 | |
CN101310186B (zh) | 测定抗原的方法和用于其的试剂盒 | |
JP5570391B2 (ja) | モノクローナル抗体及びこれを用いた免疫学的測定方法 | |
CN1215333C (zh) | 凝聚免疫分析法及其试剂 | |
CN102422159B (zh) | 用于kl-6测定的免疫测定试剂 | |
CN107817232A (zh) | 用于进行过敏症和自身免疫性疾病的诊断测定的自动化免疫分析系统 | |
JP2012026975A (ja) | Dダイマー測定用試薬 | |
CN1311438A (zh) | C-反应蛋白测定方法和测定试剂 | |
CN103025871B (zh) | 抗fdp单克隆抗体、使用其的fdp测定用试剂及试剂盒、以及fdp测定方法 | |
CN107533050A (zh) | 凝血酶‑抗凝血酶复合体的测定试剂及测定方法 | |
CN1499203A (zh) | 特异结合反应测定方法、测定装置以及其中所用试剂盒 | |
CN1189749C (zh) | 检测液体样品中抗体的方法 | |
CN1682112A (zh) | 使用荧光化抗体的荧光分析方法 | |
JP6242068B2 (ja) | ラテックス免疫凝集測定試薬 | |
CN1836163A (zh) | 亲和性物质的测定方法 | |
JP2018163064A (ja) | 異なる担持方式で固定化した抗体担持不溶性担体粒子を用いる抗原測定法、抗原測定用試薬、及び、測定用キット | |
CN111217910B (zh) | 单克隆抗体对及其在检测髓过氧化物酶蛋白中的应用 | |
JP4512492B2 (ja) | 免疫反応測定方法およびそれに用いる免疫反応測定用試薬 | |
JP2001337092A (ja) | 免疫学的測定方法及び測定用試薬 | |
CN1692281A (zh) | 免疫反应测定方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: PANASONIC HEALTHCARE + MEDICAL EQUIPMENT CO., LTD. Free format text: FORMER OWNER: MATSUSHITA ELECTRIC INDUSTRIAL CO, LTD. Effective date: 20140527 |
|
C41 | Transfer of patent application or patent right or utility model | ||
C56 | Change in the name or address of the patentee | ||
CP03 | Change of name, title or address |
Address after: Osaka Japan Patentee after: Matsushita Electric Industrial Co.,Ltd. Address before: Osaka Japan Patentee before: Matsushita Electric Industrial Co.,Ltd. |
|
TR01 | Transfer of patent right |
Effective date of registration: 20140527 Address after: Japan Ehime Prefecture Patentee after: PANASONIC Corp. Address before: Osaka Japan Patentee before: Matsushita Electric Industrial Co.,Ltd. |
|
ASS | Succession or assignment of patent right |
Owner name: PANASONIC HEALTHCARE HOLDINGS CO., LTD. Free format text: FORMER OWNER: PANASONIC HEALTHCARE + MEDICAL EQUIPMENT CO., LTD. Effective date: 20150402 |
|
TR01 | Transfer of patent right |
Effective date of registration: 20150402 Address after: Tokyo, Japan Patentee after: PANASONIC HEALTHCARE HOLDINGS CO.,LTD. Address before: Japan Ehime Prefecture Patentee before: PANASONIC Corp. |
|
CP01 | Change in the name or title of a patent holder | ||
CP01 | Change in the name or title of a patent holder |
Address after: Tokyo, Japan Patentee after: Puhexi Holdings Address before: Tokyo, Japan Patentee before: PANASONIC HEALTHCARE HOLDINGS CO.,LTD. |
|
CX01 | Expiry of patent term | ||
CX01 | Expiry of patent term |
Granted publication date: 20060329 |